ATLANTA (AP) — Next time you go for a checkup, don't be surprised if your doctor gets on your case about your weight.
The medical profession has issued new guidelines for fighting the nation's obesity epidemic, and they urge physicians to be a lot more aggressive about helping patients drop those extra pounds.
Doctors should calculate your body mass index, a weight-to-height ratio. And if you need to lose weight, they should come up with a plan and send you for counseling.
"We recognize that telling patients to lose weight is not enough," said Dr. Donna Ryan, co-chair of the guidelines committee.
The good news? By next year, most insurance companies are expected to cover counseling and other obesity treatments, following in the steps of the Medicare program, which began paying for one-on-one help last year.
More than a third of U.S. adults are obese, and that's been the case since the middle of the last decade. Officials define someone with a BMI of 30 or higher as obese. A 5-foot-9 person would be obese at 203 pounds.
Doctors are well aware that excess weight can trigger diabetes and lead to heart disease and other health problems. Yet surveys have shown that only about a third of obese patients recall their doctor talking to them about their BMI or counseling them about weight loss.
The guidelines were released this week by a group of medical organizations that include the American Heart Association, the American College of Cardiology and the Obesity Society.
They come amid a spate of important developments in the fight against obesity.
Last year, the Food and Drug Administration approved two more obesity-fighting drugs. And this year, the AMA labeled obesity a disease, a measure intended to get doctors to pay more attention to the problem and prod more insurers to pay for treatments.
Yet many people have been on their own when it comes to slimming down, left to sift through the myriad diets and exercise schemes that are promoted for weight loss. And mos
There couldn't be a bigger waste of money for these guys than a Super Bowl ad. Close to 3 million for 30 seconds, 25 of which would be taken up by mandatory legal.
It would be a good waste of money. A few years ago there was this excitement that Victoria's Secret was going to advertise on the Super Bowl. I Bought into their company and made some nice money. I know men and how they think and they set a record for the number of hits they received after that game.
Today let's look at Westfield Capital Management, an investment advisor serving institutions and wealthy investors. It employs deep fundamental research as it seeks out stocks that are underloved by the market, and its funds have outperformed their benchmarks, on average, since inception.
The company's reportable stock portfolio totaled $14.5 billion in value as of June 30, 2013.
So what does Westfield's latest quarterly 13F filing tell us? Here are a few interesting details.
The biggest new holdings are railroad company CSX and homebuilder Lennar. Other new holdings of interest include Keryx Biopharmaceuticals (NASDAQ: KERX ) , which has more than tripled over the past year and is near a 52-week high. Many expect FDA approval for its Zerenex drug, which treats kidney disease. The company is looking to expand the drug's applications and approvals, too. Keryx has potential, but so far it also has paltry revenue while it burns cash, and it doesn't have a pipeline rich with many promising drugs. Fortunately, it does have ample cash, which should support its drive toward approvals and eventual profits. If Zerenex
The Motley Fool's Market Checkup drills down on the hottest headlines and biggest market movers in the health-care sector. This episode -- featuring a special guest appearance by Dan Caplinger, The Motley Fool's director of investment planning -- highlights a biotech stock that popped 40%, gives a full examination of the Affordable Care Act's debut week, and finishes off with two stocks poised to profit from Obamacare.
In the following video, Fool health-care analyst David Williamson talks to Dan and health-care bureau chief Max Macaluso about a surprising potential winner from Obamacare. While most investors are focused on pure health-insurance plays, David notes that Walgreen (NYSE: WAG ) is quietly setting itself up to benefit from the big increase in health-care demand that's likely to result from the Patient Protection and Affordable Care Act. With millions of Americans getting insurance coverage for the first time, David believes that prescription spending will boost Walgreen's prospects, as drug coverage will help more people be able to afford drugs that they might otherwise have abandoned, such as VIVUS's (NASDAQ: VVUS ) obesity drug Qsymia